Risankizumab for Ulcerative Colitis
JAMA Author Interviews
00:00
Comparing Risankizumab to Placebo and Sequencing Therapies for Ulcerative Colitis
This chapter delves into the effectiveness of risankizumab compared to placebo in managing remission in ulcerative colitis, highlighting the complexities faced by gastroenterologists in determining the optimal treatment strategies for moderate to severe cases, considering factors like prior therapies and response to different agents.
Transcript
Play full episode
